Alectinib

ALK (Anaplastic Lymphoma Kinase) inhibitor

MECHANISM OF ACTION

Inhibits ALK tyrosine kinase and active metabolite, blocks downstream signaling therefore reducing tumor proliferation.

MECHANISM OF KIDNEY INJURY

Potential direct tubular injury

CLINICAL KIDNEY SYNDROME

Acute Kidney Injury

CARDIOVASCULAR ADVERSE EFFECTS

Bradycardia, rarely may cause peripheral edema.

LYTE ABNORMALITIES

Elevation in serum Creatinine.

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

NOTES/COMMENTS

PHARMACOKINETICS

Molecular Weight

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

Time to peak

4-6 hours

Excretion

98% fecal.

Dialyzable?

Unlikely as its >90% protein bound.

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Mohamed Ibrahim

USA

Nov 6, 2024

PARTNERS WITH